Back

Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment

27 August 2018 (13:20 - 13:35)
Organised by:
Congress Presentation Part of: PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease Lipids Open Access ESC Congress 2018

About the speaker

Photo
Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?
Professor P. Steg (Paris, FR)
Slides Video
Presentation thumbnail
Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.
Professor D. Bhatt (New York City, US)

Access the full session

Session thumbnail
PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

The Event

Event poster

ESC Congress 2018

27 August 2018 13:20 CET
You may be interested in
thumbnail
Congress Presentation
Boosting secondary prevention: efficacy and adherence of inclisiran in post-acute coronary syndrome very high-risk patients
3 April 2025
thumbnail
Congress Presentation
Update on LDL-C-lowering drugs and combinations
31 August 2025
thumbnail
Congress Presentation
Awareness of lipid guideline recommendations for high-risk patients amongst primary care physicians in Canada
28 August 2022
thumbnail
Congress Presentation
Real-world use of rosuvastatin 40 mg and ezetimibe 10 mg after ACS: is this combination effective in achieving guideline-recommended LDL-C goals after discharge?
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources